Boan bio-new crown and antibody completed Phase I clinical all subjects into the group

Severe Acute Respiratory Syndrome Coronary Virus 2 (SARS-CoV-2) has caused a pandemic of new coronavirus pneumonia, which pose a significant threat to the health and economy of people around the world.
LY-CovMab is a recombinant all-human monoclonal neutralizing antibody that binds to the SARS-CoV-2 surface prick protein culture with high affinity specificity, and effectively blocks the binding of the virus to the host cell surface subject ACE2.
preclinical efficacy study of LY-CovMab showed that LY-CovMab was effective in treating and preventing SARS-CoV-2 infection.
LY-CovMab is a highly potency medium antibody that responds effectively to viral mutations.
addition, LY-CovMab is effective in avoiding ADE effects (enhanced antibody dependence).
antibody therapy has the dual role of prevention and treatment compared to new coronary vaccines and antiviral drugs.
the current protection rate of the new crown vaccine can not reach 100%, so before and after the new crown vaccine, the antibody therapy can be used to treat new coronavirus infections.
addition, one of the great advantages of meso-antibodies is that they work quickly.
Compared to most new coronary vaccines requiring two injections, and after two months to produce a stable immune response, the use of antibodies for prevention, can quickly produce passive immunity, is expected to be suitable for vaccination of specific high-risk groups or close contacts of new coronary infections to provide good protection.
the outbreak of neo-crown pneumonia, The Green Leaf Pharmaceutical Group moved quickly, in addition to the first time donations, but also in drug research and development, social welfare and other aspects of the fight against the "epidemic" continued to contribute professional strength.
Boan Bio is one of the first innovative biopharmaceian enterprises in China to carry out research and development of new coronary antibodies.
, LY-CovMab has been included in the Ministry of Science and Technology's "New Coronavirus and Antibody Product Development Emergency Program", which will accelerate its research and development and market speed, as soon as possible to provide effective treatment solutions for the vast number of patients.
addition to China, Boan Bio will also conduct clinical research in the United States to advance its global listing.
LY-CovMab was developed by Boan Bio's all-human antibody genetically modified mouse phage demonstration technology platform.
"all-human antibody genetically modified mice" is a patented technology of Boan biological, and in the domestic leading level.
The use of Boan bio-owned all-human antibody genetically modified mice BA-hMab screening out of antibodies, without the need for traditional humanization process, from the Spice protein immunity to block the obtain of antibodies only took more than 40 days, greatly improving the speed of antibody development.
addition, LY-CovMab uses a special Fc sequence design to avoid the enhanced effects of antibody dependence and the increased cytokine storms used by viruses, thereby improving the safety of antibody drugs and the success rate of their eventual market.
note: There are deletions in the original text